SRR1488836
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.634
- IL6_JAK_STAT3_SIGNALING+0.599
- CHOLESTEROL_HOMEOSTASIS+0.564
- INFLAMMATORY_RESPONSE+0.562
- ANGIOGENESIS+0.549
- ALLOGRAFT_REJECTION+0.546
- HYPOXIA+0.537
- INTERFERON_GAMMA_RESPONSE+0.526
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.505
- IL2_STAT5_SIGNALING+0.501
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.368
- SPERMATOGENESIS-0.300
- DNA_REPAIR-0.178
- PANCREAS_BETA_CELLS-0.175
- HEDGEHOG_SIGNALING-0.134
- KRAS_SIGNALING_DN-0.134
- MYC_TARGETS_V2-0.104
- NOTCH_SIGNALING+0.011
- PEROXISOME+0.119
- E2F_TARGETS+0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR660895 | GTEX | — | 0.954 |
| 2 | BS_WRHDP7WF | Posterior Fossa Ependymoma | — | 0.940 |
| 3 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.932 |
| 4 | EPT0509 | EPN | EPN Tumor | 0.930 |
| 5 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.929 |
| 6 | s_150324_4b | EPN | Posterior Fossa EPN | 0.929 |
| 7 | SRR934952 | — | — | 0.917 |
| 8 | SRR934729 | — | — | 0.916 |
| 9 | SRR934866 | — | — | 0.914 |
| 10 | BS_1JDG6JV5 | pilocytic astrocytoma | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.634 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.599 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.564 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.562 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.549 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.546 | Idelalisib | — uncovered |
| HYPOXIA | 0.537 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.526 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.505 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.501 | Idelalisib | — uncovered |
| APOPTOSIS | 0.472 | Idelalisib | — uncovered |
| COMPLEMENT | 0.465 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.432 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.431 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.426 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.425 | Inavolisib | — uncovered |
| COAGULATION | 0.409 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.386 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.368 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.354 | Inavolisib | — uncovered |